Media coverage about Collegium Pharmaceutical (NASDAQ:COLL) has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Collegium Pharmaceutical earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned media stories about the specialty pharmaceutical company an impact score of 47.3240867095092 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the news articles that may have effected Accern’s rankings:

How to Become a New Pot Stock Millionaire

Collegium Pharmaceutical (NASDAQ COLL) traded down $0.19 during trading hours on Monday, hitting $23.18. 396,983 shares of the stock were exchanged, compared to its average volume of 660,941. The company has a market cap of $754.79 and a PE ratio of -7.80. Collegium Pharmaceutical has a twelve month low of $7.37 and a twelve month high of $26.77.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.28. The company had revenue of $11.95 million during the quarter, compared to analysts’ expectations of $5.31 million. Collegium Pharmaceutical had a negative net margin of 447.83% and a negative return on equity of 77.11%. Collegium Pharmaceutical’s revenue for the quarter was up 2814.6% on a year-over-year basis. During the same period last year, the business earned ($1.13) EPS. sell-side analysts predict that Collegium Pharmaceutical will post -2.52 earnings per share for the current year.

COLL has been the topic of a number of research reports. Piper Jaffray Companies set a $33.00 target price on shares of Collegium Pharmaceutical and gave the company a “buy” rating in a research report on Tuesday, January 23rd. Zacks Investment Research raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $16.00 target price on the stock in a research report on Monday, November 13th. Jefferies Group raised their target price on shares of Collegium Pharmaceutical to $27.00 and gave the company a “buy” rating in a research report on Tuesday, December 5th. Needham & Company LLC raised their target price on shares of Collegium Pharmaceutical from $25.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, December 5th. They noted that the move was a valuation call. Finally, HC Wainwright restated a “buy” rating and issued a $21.00 price target on shares of Collegium Pharmaceutical in a report on Wednesday, November 8th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $25.00.

In other Collegium Pharmaceutical news, insider Alison B. Fleming sold 6,928 shares of Collegium Pharmaceutical stock in a transaction that occurred on Wednesday, January 10th. The shares were sold at an average price of $19.07, for a total transaction of $132,116.96. Following the completion of the sale, the insider now directly owns 32,651 shares in the company, valued at approximately $622,654.57. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Chairman Michael Thomas Heffernan sold 20,000 shares of Collegium Pharmaceutical stock in a transaction that occurred on Tuesday, January 23rd. The shares were sold at an average price of $25.01, for a total transaction of $500,200.00. Following the sale, the chairman now owns 535,395 shares of the company’s stock, valued at $13,390,228.95. The disclosure for this sale can be found here. Insiders sold a total of 1,105,558 shares of company stock valued at $19,346,677 over the last quarter. 25.76% of the stock is owned by company insiders.

TRADEMARK VIOLATION WARNING: “Collegium Pharmaceutical (COLL) Earning Somewhat Positive News Coverage, Study Shows” was originally posted by Marea Informative and is the property of of Marea Informative. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://www.mareainformativa.com/2018/01/30/collegium-pharmaceutical-coll-earning-somewhat-favorable-press-coverage-analysis-finds-updated-updated-updated.html.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Insider Buying and Selling by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.